Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
1992-7-14
pubmed:abstractText
We studied the influence of the lipid/amphotericin B (AMB) ratio and the phospholipid type on the in vitro renal cell toxicity and antifungal efficacy of lipid-associated AMB (L-AMB). L-AMB was prepared at one of two different lipid/AMB ratios (1 and 40) by incubating AMB with empty small unilamellar vesicles, made from one of three different phospholipids: dipalmitoyl-, dimirystoyl-, and distearoylphosphatidylcholine (DPPC, DMPC, and DSPC, respectively). Renal cell toxicity, investigated through an assessment of the Na-dependent uptake of phosphate by proximal tubular cells, and fungicidal effect against Candida albicans were studied after 1 h of treatment at 37 degrees C. The amount of unbound AMB present in each L-AMB formulation was studied by use of circular dichroism. At a lipid/AMB ratio of 40, the three lipidic formulations were not toxic for renal cells but were less effective against C. albicans than AMB; however, DSPC-AMB, which contained 50% unbound AMB, was more effective against C. albicans than DPCC-AMB or DMPC-AMB, containing 0 and 13% unbound AMB, respectively. At a lipid/AMB ratio of 1, the antifungal effects of L-AMB and AMB were similar, whatever the phospholipid used, but only DMPC-AMB remained highly protective against AMB renal cell toxicity, despite the presence of the same amount of unbound AMB (50%) in DMPC-AMB and DPPC-AMB. We conclude that the in vitro activities and renal cell toxicities of different L-AMB formulations are influenced by the phospholipid type and the lipid/AMB ratio. The optimal ratio depends on the phospholipid itself. At a lipid/AMB ratio of 40, the antifungal activity depends mainly on the amount of unbound AMB in the formulation. At a lipid/AMB ratio of 1, the renal cell toxicity also depends on the fluidity of the phospholipid.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/1605590-2183713, http://linkedlifedata.com/resource/pubmed/commentcorrection/1605590-2213553, http://linkedlifedata.com/resource/pubmed/commentcorrection/1605590-2324537, http://linkedlifedata.com/resource/pubmed/commentcorrection/1605590-2449867, http://linkedlifedata.com/resource/pubmed/commentcorrection/1605590-2537298, http://linkedlifedata.com/resource/pubmed/commentcorrection/1605590-2658784, http://linkedlifedata.com/resource/pubmed/commentcorrection/1605590-2795463, http://linkedlifedata.com/resource/pubmed/commentcorrection/1605590-3189764, http://linkedlifedata.com/resource/pubmed/commentcorrection/1605590-3303926, http://linkedlifedata.com/resource/pubmed/commentcorrection/1605590-3383959, http://linkedlifedata.com/resource/pubmed/commentcorrection/1605590-3413081, http://linkedlifedata.com/resource/pubmed/commentcorrection/1605590-3419424, http://linkedlifedata.com/resource/pubmed/commentcorrection/1605590-3539192, http://linkedlifedata.com/resource/pubmed/commentcorrection/1605590-3579259, http://linkedlifedata.com/resource/pubmed/commentcorrection/1605590-3806172, http://linkedlifedata.com/resource/pubmed/commentcorrection/1605590-3807887, http://linkedlifedata.com/resource/pubmed/commentcorrection/1605590-3903941, http://linkedlifedata.com/resource/pubmed/commentcorrection/1605590-6307124, http://linkedlifedata.com/resource/pubmed/commentcorrection/1605590-6372684, http://linkedlifedata.com/resource/pubmed/commentcorrection/1605590-6385839, http://linkedlifedata.com/resource/pubmed/commentcorrection/1605590-6842027, http://linkedlifedata.com/resource/pubmed/commentcorrection/1605590-6871175, http://linkedlifedata.com/resource/pubmed/commentcorrection/1605590-7081822, http://linkedlifedata.com/resource/pubmed/commentcorrection/1605590-942051
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
0066-4804
pubmed:author
pubmed:issnType
Print
pubmed:volume
36
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
262-6
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
1992
pubmed:articleTitle
Influence of phospholipid/amphotericin B ratio and phospholipid type on in vitro renal cell toxicities and fungicidal activities of lipid-associated amphotericin B formulations.
pubmed:affiliation
Laboratoire d'Etude des Traitements Antiinfectieux, Faculté Xavier Bichat, Université Paris 7, France.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't